China’s blueprint for a checkpoint blocker price war
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
Rebate ban would not necessarily equal savings, Icer says
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
The Gottlieb legacy: a surge in unproven treatments?
Many in the biopharma sector will rue the departure of Scott Gottlieb, an FDA commissioner who pursed a permissive path for novel drugs at the US regulator. Will his…
Lilly takes a leaf out of Mylan’s book to defuse insulin price complaints
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Big pharma execs decry rebates, but how big might list price cuts be?
Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
Adcom gives Karyopharm a second chance with selinexor
Incredibly, a US FDA panel has left the door open for approval of Karyopharm’s selinexor in multiple myeloma, despite concerns about safety.
Xeljanz warning Jaks up safety concerns
An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
Regeneron and Sanofi play follow the leader on Praluent pricing
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.
The list of shame no biopharma wants to join
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.